索非布韦+达卡他韦治疗丙型肝炎肝硬化失代偿期患者的疗效观察

The response to Sofosbuvir plus Daklinza therapy in decompensated cirrhosis related to chronic hepatitis C

目的观察索非布韦+达卡他韦治疗丙型肝炎肝硬化失代偿期的疗效。方法对2015年8月~2016年12月德宏州人民医院感染科住院部86名丙型肝炎肝硬化失代偿期患者进行索非布韦+达卡他韦抗病毒治疗,进行回顾性分析其对抗病毒治疗的应答(包括EVR、SVR、ETVR)、复发及影响抗病毒治疗的因素。结果患者治疗第4周均实现快速病毒学应答RVR。82名(95%)患者获得持续病毒学应答(抗病毒结束治疗12周HCVRNA<1 000 IU/ml)。治疗前后患者血象稳定,无血细胞减少的情况出现。结论对于丙型肝炎肝硬化失代偿期索非布韦+达卡他韦抗病毒安全有效。

Objective To observe the effect of the response to Sofosbuvir+Daklinza therapy in decompensated cirrhosis related to chronic hepatitis C(CHC)in the People's Hospital of Dehong District.Methods 86 patients with decompensated cirrhosis related to chronic hepatitis C who accepted Sofosbuvir plus Daklinza therapy enrolled from August 2015 to December 2016 in infectious diseases department of Dehong Peoples,hospital were collected.We analyzed retrospectively response to antiviral therapy including sustained virologic response(SVR),early virologic response(EVR),end of treatment virologic response(ETVR)and relapse as well as the factor about impact of antiviral therapy.Results A rapid virological response RVR was achieved in the 4th week of treatment.82(95%)patients achieved a sustained virologic response(HCV RNA<1 000 IU/ml at 12 weeks of end-of-antiviral treatment).Before and after treatment,the patient's blood was stable and there was no reduction of blood cells.Conclusion Sofosbuvir plus Daklinza therapy in decompensated cirrhosis related to chronic hepatitis C is safe and effected.